Author Archives: pancreatica
A Setback for ARBs for the Treatment of Pancreatic Cancer?
Again, for more than a decade there have been theoretical discussions about the use of drugs commonly used to treat high blood pressure for use in the treatment of cancer – pancreatic cancer (ductal adenocarcinoma of the pancreas). And having just published a Pancreatica blog entry based on the pre-clinical study and work by Jain […]
ARBs for the Treatment of Pancreatic Cancer?
For more than a decade there have been theoretical discussions about the use of drugs commonly used to treat high blood pressure for use in the treatment of cancer – pancreatic cancer (ductal adenocarcinoma of the pancreas). And there have been some prior preliminary research studies. Now comes a very intriguing and elaborate pre-clinical study […]
Nanoliposomal Topoisomerase I Inhibitor for Advanced Pancreatic Cancer
There is no universally agreed upon second line treatment for metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas). On August 20 2013 in the British Journal of Cancer, the results of an interesting international Phase II clinic trial using nanoliposomal irinotecan for the treatment of earlier pre-treated metastatic pancreatic cancer were published. The researchers included […]
EUS for Neuroendocrine Tumors
Depending on who you are and how you count, there are almost twenty kinds of pancreatic cancer. The main two that we generally speak of are ductal adenocarcinoma of the pancreas which arises from the non-hormonal part of the organ and may be responsible for as much as 85% of cases, and pancreatic neuroendocrine tumors […]
IA and IV Gemcitabine plus Mitomycin-C for Pancreatic Cancer
Recent advances over the drug agent gemcitabine for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) are still in progress but the current strong regimins for first-line therapy appear to include the FOLFIRINOX (5-FU based) combination regimen, and now recently Abraxane plus gemcitabine. Now comes a study by German researchers Lorenz and colleagues from the […]